The Role of Laboratory, Pharmacy, and Nutrition Services in the Comprehensive Management of Metabolic Syndrome A Narrative Review

Authors

  • Rawan Abdulaziz ALNAKHLI
  • Mahmoud Faleh A ALNAKHLI
  • Wasmiah Faihan Muzwid ALANAZI
  • Hassan Gihzi ALHAJUOJ
  • Aldghmani, Abdulmajeed Eid M
  • Fahad Riffia Sh ALENEZI
  • Saud Saleh Mishal ALSHAMMARI
  • Mohammed Hashim Bador ALMADANI
  • Naif Suwailem Salem ALANAZI
  • Ali Yaseen Al BAHRANI
  • Abdullah Asir A. ALANAZI

DOI:

https://doi.org/10.22399/ijcesen.3911

Keywords:

Metabolic Syndrome X, Interdisciplinary Health Team, Clinical Laboratory Services, Pharmacy Services, Nutrition Therapy, Personalized Medicine

Abstract

Metabolic syndrome, a constellation of interrelated risk factors including central obesity, insulin resistance, dyslipidemia, and hypertension, demands an integrated, multidisciplinary approach for effective management. Laboratory services form the backbone of diagnosis and monitoring, providing essential biochemical and hematologic markers—such as fasting glucose, HbA1c, lipid profile, liver enzymes, and inflammatory markers—that guide risk stratification and therapeutic decisions. Regular, standardized testing enables early detection of metabolic derangements, tracks response to interventions, and identifies medication-related adverse effects, thereby facilitating timely adjustments in care. Moreover, laboratory-driven population surveillance supports preventive strategies and the evaluation of programmatic outcomes across clinical settings. Pharmacy and nutrition services complement laboratory input by translating diagnostic information into individualized, evidence-based treatment plans. Pharmacists optimize medication regimens for glycemic control, blood pressure, and dyslipidemia while minimizing polypharmacy risks through medication reconciliation, adherence support, and counseling on side effects and drug–nutrient interactions. Nutrition professionals deliver tailored dietary interventions—focusing on caloric balance, macronutrient composition, and culturally appropriate food choices—that target weight reduction, improve insulin sensitivity, and correct lipid abnormalities. When coordinated effectively, these three services foster a continuous cycle of assessment, intervention, and reassessment, enhancing patient engagement, improving clinical outcomes, and reducing long-term cardiometabolic complications associated with metabolic syndrome.

References

[1] Witchel S.F., Oberfield S.E., Peña A.S, (2019). Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J. Endocr. Soc. 3:1545–1573. doi: 10.1210/js.2019-00078.

[2] Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., et al., (2006). Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. J. Clin. Endocrinol. Metab. 91:4237–4245. doi: 10.1210/jc.2006-0178.

[3] Rajiah K., Sivarasa S., Maharajan M.K, (2021). Impact of Pharmacists’ Interventions and Patients’ Decision on Health Outcomes in Terms of Medication Adherence and Quality Use of Medicines among Patients Attending Community Pharmacies: A Systematic Review. Int. J. Environ. Res. Public Health. 18:4392. doi: 10.3390/ijerph18094392.

[4] Ferrar i R, (2015). Writing Narrative Style Literature Reviews. Med. Writ. 24:230–235. doi: 10.1179/2047480615Z.000000000329.

[5] Gambineri A., Patton L., Altieri P., Pagotto U., Pizzi C., Manzoli L., Pasquali R, (2012). Polycystic Ovary Syndrome Is a Risk Factor for Type 2 Diabetes. Diabetes. 61:2369–2374. doi: 10.2337/db11-1360.

[6] Helvaci N., Yildiz B.O, (2023). Current and Emerging Drug Treatment Strategies for Polycystic Ovary Syndrome. Expert Opin. Pharmacother. 24:105–120. doi: 10.1080/14656566.2022.2108702.

[7] Schumacher P.M., Becker N., Tsuyuki R.T., Griese-Mammen N., Koshman S.L., McDonald M.A., Bouvy M., Rutten F.H., Laufs U., Böhm M., et al., (2021). The Evidence for Pharmacist Care in Outpatients with Heart Failure: A Systematic Review and Meta-Analysis. ESC Heart Fail. 8:3566–3576. doi: 10.1002/ehf2.13508.

[8] Christ J.P., Cedars M.I, (2023). Current Guidelines for Diagnosing PCOS. Diagnostics. 13:1113. doi: 10.3390/diagnostics13061113.

[9] Sanchez-Garrido M.A., Tena-Sempere M., (2020). Metabolic Dysfunction in Polycystic Ovary Syndrome: Pathogenic Role of Androgen Excess and Potential Therapeutic Strategies. Mol. Metab. 35:100937. doi: 10.1016/j.molmet.2020.01.001.

[10] Stuhec M., Tement V, (2021). Positive Evidence for Clinical Pharmacist Interventions during Interdisciplinary Rounding at a Psychiatric Hospital. Sci. Rep. 11:13641. doi: 10.1038/s41598-021-92909-2.

[11] Salari N., Nankali A., Ghanbari A., Jafarpour S., Ghasemi H., Dokaneheifard S., Mohammadi M, (2024). Global Prevalence of Polycystic Ovary Syndrome in Women Worldwide: A Comprehensive Systematic Review and Meta-Analysis. Arch. Gynecol. Obstet. 310:1303–1314. doi: 10.1007/s00404-024-07607-x.

[12] Anbar H.S., Vahora N.Y., Shah H.I., Azam M.M., Islam T., Hersi F., Omar H.A., Dohle W., Potter B.V.L., El-Gamal M.I, (2023). Promising Drug Candidates for the Treatment of Polycystic Ovary Syndrome (PCOS) as Alternatives to the Classical Medication Metformin. Eur. J. Pharmacol. 960:176119. doi: 10.1016/j.ejphar.2023.176119.

[13] Mumusoglu S., Yildiz B.O, (2020). Polycystic Ovary Syndrome Phenotypes and Prevalence: Differential Impact of Diagnostic Criteria and Clinical versus Unselected Population. Curr. Opin. Endocr. Metab. Res. 12:66–71. doi: 10.1016/j.coemr.2020.03.004.

[14] Sachdeva G., Gainder S., Suri V., Sachdeva N., Chopra S, (2019). Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and Their Response to Clomiphene. Indian J. Endocrinol. Metab. 23:326. doi: 10.4103/ijem.IJEM_30_19.

[15] PCNE The PCNE Classification V 9.1 2020.

[16] Barber T.M., Hanson P., Weickert M.O., Franks S, (2019). Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clin. Med. Insights Reprod. Health. 13:1179558119874042. doi: 10.1177/1179558119874042.

[17] Espinosa M.E., Sánchez R., Otzen T., Bautista-Valarezo E., Aguiar S., Corrales-Gutierrez I., Leon-Larios F., Manterola C, (2024). Phenotypic Characterization of Patients with Polycystic Ovary Syndrome in a Population from the Ecuadorian Andes: A Cross-Sectional Study. J. Clin. Med. 13:2376. doi: 10.3390/jcm13082376.

[18] Ahmed A., Saqlain M., Tanveer M., Blebil A.Q., Dujaili J.A., Hasan S.S, (2021). The Impact of Clinical Pharmacist Services on Patient Health Outcomes in Pakistan: A Systematic Review. BMC Health Serv. Res. 21:859. doi: 10.1186/s12913-021-06897-0.

[19] Sirmans S.M., Pate K.A, (2013). Epidemiology, Diagnosis, and Management of Polycystic Ovary Syndrome. Clin. Epidemiol. 6:1–13. doi: 10.2147/CLEP.S37559.

[20] Rashid R., Mir S.A., Kareem O., Ali T., Ara R., Malik A., Amin F., Bader G.N, (2022). Polycystic Ovarian Syndrome-Current Pharmacotherapy and Clinical Implications. Taiwan. J. Obstet. Gynecol. 61:40–50. doi: 10.1016/j.tjog.2021.11.009.

[21] Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K, (2013). Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 98:4565–4592. doi: 10.1210/jc.2013-2350.

[22] Kim J.J., (2024). Obesity and Polycystic Ovary Syndrome. J. Obes. Metab. Syndr. 33:289–301. doi: 10.7570/jomes24035.

[23] Coons L.M., Loucks J, (2023). Role and Impact of a Clinical Pharmacist in an Ambulatory Reproductive Endocrinology and Infertility Clinic. Am. J. Health Syst. Pharm. 80:1206–1212. doi: 10.1093/ajhp/zxad133.

[24] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome. (2024). Fertil. Steril. 81:19–25. doi: 10.1016/j.fertnstert.2003.10.004.

[25] Ye J. Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle. (2007) Endocr. Metab. Immune Disord. Drug Targets. 7:65–74. doi: 10.2174/187153007780059423

[26] McCracken E, Monaghan M, Sreenivasan S, (2018). Pathophysiology of the metabolic syndrome. Clin. Dermatol. 36:14–20. doi: 10.1016/j.clindermatol.2017.09.004

[27] Huth C, Pigeon É, Riou M-È, St-Onge J, Arguin H, Couillard E, et al., (2016). Fitness, adiposopathy, and adiposity are independent predictors of insulin sensitivity in middle-aged men without diabetes. J. Physiol. Biochem. 72:435–44. doi: 10.1007/s13105-016-0488-2

[28] Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al., (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 288:2709–16. doi: 10.1001/jama.288.21.2709

[29] Vaidya RA, Desai S, Moitra P, Salis S, Agashe S, Battalwar R, et al., (2023). Hyperinsulinemia: an early biomarker of metabolic dysfunction. Front. Clin. Diabetes Healthc. 4:1159664. doi: 10.3389/fcdhc.2023.1159664

[30] Agyemang-Yeboah F, Eghan BA, Annani-Akollor ME, Togbe E, Donkor S, Afranie BO, (2019). Evaluation of metabolic syndrome and its associated risk factors in type 2 diabetes: A descriptive cross-sectional study at the Komfo Anokye Teaching Hospital, Kumasi, Ghana. BioMed. Res. Int. 4562904. doi: 10.1155/2019/4562904

[31] Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al., (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24:683–9. doi: 10.2337/diacare.24.4.683

[32] Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, et al., (2008). Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol. 28:1039–49. doi: 10.1161/ATVBAHA.107.159228

[33] Catalano KJ, Maddux BA, Szary J, Youngren JF, Goldfine ID, Schaufele F, (2014). Insulin resistance induced by hyperinsulinemia coincides with a persistent alteration at the insulin receptor tyrosine kinase domain. PloS One. 9:e108693. doi: 10.1371/journal.pone.0108693

[34] Mottillo S, Filion KB, Genest J, Genest J, Joseph L, Pilote L, et al., (2010). The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 56:1113–32. doi: 10.1016/j.jacc.2010.05.034

[35] Charkos TG, Getnet M, (2023). Metabolic syndrome in patients with type 2 diabetes mellitus at Adama Hospital Medical College, Ethiopia: a hospital-based cross-sectional study. Front. Clin. Diabetes Healthc. 4:1165015. doi: 10.3389/fcdhc.2023.1165015

[36] Eckel RH, Grundy SM, Zimmet PZ, (2005). The metabolic syndrome. Lancet. 365:1415–28. doi: 10.1016/S0140-6736(05)66378-7

[37] Kanjilal S, Shanker J, Rao VS, Khadrinarasimhaih NB, Mukherjee M, Iyengar SS, et al., (2008). Prevalence and component analysis of metabolic syndrome: an Indian atherosclerosis research study perspective. Vasc. Health Risk Manage. 4:189–97. doi: 10.2147/vhrm.2008.04.01.189

[38] Moore JX, Chaudhary N, Akinyemiju T, (2017). Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev. Chronic Dis. 14:160287. doi: 10.5888/pcd14.160287

[39] Ellulu MS, Khaza'ai H, Rahmat A, Patimah I, Abed Y, (2016). Obesity can predict and promote systemic inflammation in healthy adults. Int. J. Cardiol. 215:318–24. doi: 10.1016/j.ijcard.2016.04.089

[40] Foster-Powell K, Holt SH, Brand-Miller JC, (2016). International table of glycemic index and glycemic load values. Am J Clin Nutr. 76:5–56. doi: 10.1093/ajcn/76.1.5.

[41] Hepler CD, Strand LM, (1990). Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 47(3):533–43.

[42] Tumkur A, Pm M, Shetty R, Naik A, (2012). Pharmaceutical care: need of the hour in India. J Young Pharmacists. 4:282–6. doi: 10.4103/0975-1483.104374.

[43] Bantle JP, Wylie-Rosett J, Albright A, Apovian CM, Clark NG, (2008). American Diabetes Association et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 31(Suppl. 1):S61–S78. doi: 10.2337/dc08-S061.

[44] Kaveeshwar S, Cornwall J, (2014). The current state of diabetes mellitus in India. Australas Med J. 7(1):45–48. doi: 10.4066/AMJ.2014.1979.

[45] Suckling RJ, He FJ, Macgregor GA, (2010). Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 12:Cd006763. doi: 10.1002/14651858.CD006763.pub2.

[46] JD K. (2001). National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 37(1 Suppl 2):S66–70. doi: 10.1053/ajkd.2001.20748.

[47] Nugent R. (2008). Chronic diseases in developing countries health and economic burdens. New York Academy of Sciences. 1136:70–79. doi: 10.1196/annals.1425.027.

[48] Analava Mitra. (2003). Food Habits: Some Relationship to Diabetes and Heart Diseases. Anthropologist Special Vol(3). 109–122.

[49] Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. (2007). Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 125(3):217–30.

[50] Luthra D. (2010). A link between stress and diabetes. Webmedcentral Psychiatry. 1(10):Wmc001095.

[51] American Diabetes Association. (2012). Standards of medical care in diabetes—2013. Diabetes Care. 36:S11–66. doi: 10.2337/dc13-S011.

[52] Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. (2012). Pharmacists' interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant. 27(1):276–292. doi: 10.1093/ndt/gfr287.

[53] Suckling RJ, He FJ, Macgregor GA, (2010). Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 12:Cd006763. doi: 10.1002/14651858.CD006763.pub2.

[54] Kc D, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K, (2009). Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes. 10(Suppl. 12):195–203. doi: 10.1111/j.1399-5448.2009.00576.x.

[55] Fowler MJ. (2008). Microvascular and macrovascular complications of diabetes. Clin Diabetes. 26:2.

[56] Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al., (2004). Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 110:1245–1250. doi: 10.1161/01.CIR.0000140677.20606.0E

[57] Després JP, Lemieux I., (2006). Abdominal obesity and metabolic syndrome. Nature. 444:881–887. doi: 10.1038/nature05488

[58] Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 105:141–150. doi: 10.1016/j.diabres.2014.04.006

[59] Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr, Wilson PW. (2005). Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes. 54:3252–3257. doi: 10.2337/diabetes.54.11.3252

[60] Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al., (2007). Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 49:403–414. doi: 10.1016/j.jacc.2006.09.032

[61] Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, et al., (2015). The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol. 66:1050–1067. doi: 10.1016/j.jacc.2015.06.1328

[62] Grundy SM. (2008). Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 28:629–636. doi: 10.1161/ATVBAHA.107.151092

[63] Kim LJ, Nalls MA, Eiriksdottir G, Sigurdsson S, Launer LJ, Koster A, et al. (2011). Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik study. Obesity (Silver Spring). 19:1265–1271. doi: 10.1038/oby.2010.291

[64] Esser N, Paquot N, Scheen AJ, (2015). Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 24:283–307. doi: 10.1517/13543784.2015.974804

[65] Dommermuth R, Ewing K., (2018). Metabolic syndrome: systems thinking in heart disease. Prim Care. 45:109–129. doi: 10.1016/j.pop.2017.10.003Stenholm S, Koster A, Alley DE, Visser M, Maggio M, Harris TB, et al., (2010). Adipocytokines and the metabolic syndrome among older persons with and without obesity: the InCHIANTI study. Clin Endocrinol (Oxf). 73:55–65. doi: 10.1111/j.1365-2265.2009.03742.x

[66] Grundy SM., (2016). Overnutrition, ectopic lipid and the metabolic syndrome. J Investig Med. 64:1082–1086. doi: 10.1136/jim-2016-000155

[67] D'Adamo E, Marcovecchio ML, Giannini C, Capanna R, Impicciatore M, Chiarelli F, et al., (2010). The possible role of liver steatosis in defining metabolic syndrome in prepubertal children. Metabolism. 59:671–676. doi: 10.1016/j.metabol.2009.09.012

Downloads

Published

2024-12-30

How to Cite

Rawan Abdulaziz ALNAKHLI, Mahmoud Faleh A ALNAKHLI, Wasmiah Faihan Muzwid ALANAZI, Hassan Gihzi ALHAJUOJ, Aldghmani, Abdulmajeed Eid M, Fahad Riffia Sh ALENEZI, … Abdullah Asir A. ALANAZI. (2024). The Role of Laboratory, Pharmacy, and Nutrition Services in the Comprehensive Management of Metabolic Syndrome A Narrative Review. International Journal of Computational and Experimental Science and Engineering, 10(4). https://doi.org/10.22399/ijcesen.3911

Issue

Vol. 10 No. 4 (2024): IJCESEN

Section

Research Article

License

Copyright (c) 2024 International Journal of Computational and Experimental Science and Engineering

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.